View Post

The Next-Generation Promise of ADCs and SERDs in Breast Cancer

In In The News by Barbara Jacoby

By: Lisa Astor From: targetedonc.com The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer. In 2022, development of novel targeted therapies has focused on antibody-drug conjugates (ADCs) and selective estrogen receptor degraders (SERDs). Both classes of agents have shown mixed efficacy over time. The generation in development offers reasons for excitement about improved …

View Post

SABCS Trials Show Improved Outcomes in Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com Oral selective estrogen receptor downregulators, or SERDs as they’re known, have now come into the market and are coming out of trials, I should say, and are being tested in phase II and now in phase III trials. The first one to report mature data from the phase III trial was elacestrant [Orserdu], which was …

View Post

SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jason Harris From: onclive.com Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer. Selective estrogen receptor degraders (SERDs) are becoming increasingly important in the treatment of ER-positive metastatic breast cancer (MBC), Erika P. Hamilton, MD, said during a presentation at the 20th Annual International Congress on the Future of Breast Cancer® East …